A phase 3, double-blind, randomized placebo-controlled efficacy and safety study of abiraterone acetate in chemotherapy-naïve patients with mCRPC in China, Malaysia, Thailand and Russia

OBJECTIVE: This double-blind, placebo-controlled phase 3 study was designed to compare efficacy and safety of abiraterone acetate + prednisone (abiraterone) to prednisone alone in chemotherapy-naïve, asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer (mCRPC) patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Ye, Dingwei, Huang, Yiran, Zhou, Fangjian, Xie, Keji, Matveev, Vsevolod, Li, Changling, Alexeev, Boris, Tian, Ye, Qiu, Mingxing, Li, Hanzhong, Zhou, Tie, De Porre, Peter, Yu, Margaret, Naini, Vahid, Liang, Hongchuan, Wu, Zhuli, Sun, Yinghao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Second Military Medical University 2017
Materias:
Asian Focus
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5717983/
https://www.ncbi.nlm.nih.gov/pubmed/29264210
http://dx.doi.org/10.1016/j.ajur.2017.01.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5717983/
https://www.ncbi.nlm.nih.gov/pubmed/29264210
http://dx.doi.org/10.1016/j.ajur.2017.01.002

Ejemplares similares